Indegene reported strong Q3 FY26 results, with revenue rising to INR 9,421 million, a 30.8% year-on-year increase. Adjusted EBITDA margin was 18.5%. The company secured significant new deals, including omnichannel orchestration for a top pharma company and a product launch for an emerging pharma, each exceeding $10 million. Indegene is integrating Gen AI to enhance productivity and expand its service offerings.
Financial Performance
Indegene’s revenue for Q3 FY26 reached INR 9,421 million, reflecting a robust 30.8% year-on-year growth and 17.1% quarter-on-quarter growth. In USD terms, revenue increased by 24.4% year-on-year. Adjusted EBITDA came in at INR 1,747 million, with margins expanding to 18.5%. The company’s revenue per employee crossed $70,000 annual mark. PAT for the quarter was INR 1,026 million.
Key Business Highlights
The company won seven large deals exceeding $1 million ACV each across three accounts during Q3. This includes omnichannel orchestration for a top 10 pharma company and a product launch engagement for an emerging pharma, each expected to yield $10 million plus in annual revenues. A medical device customer is utilizing Indegene’s AI-driven automation for pharmacovigilance workflows. Indegene is also setting up a global innovation center for a mid-sized pharma customer. The active customer base grew to 86, and the number of $1 million-plus customers increased to 52.
Strategic Initiatives and Outlook
Indegene is integrating Gen AI across its commercial and medical segments to drive productivity gains. The company is expanding its catalogues to convert productivity into volume expansion. Integration of BioPharm is on track, with cost synergies totaling around $1 million per annum expected in FY27. The company has integrated Brand Activation and BioPharm into the Enterprise Commercial Segment.
Segment Performance
Going forward, the company will report results under three segments: Enterprise Commercial, Enterprise Medical, and Others. North America accounted for 71.8% of revenues, and Europe contributed 25.5%.
Leadership Commentary
Management indicated that they are positioning Indegene as a strategic partner to deliver superior outcomes through Gen AI platforms. They anticipate a stable industry growth outlook with strong innovation momentum. Despite policy-driven headlines, the impact on Indegene has been minimal.
Source: BSE
